MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients

• DOI: 10.1186/s13000-015-0447-1
• Publication Date: 2015-12-30T01:41:41Z
• Authors: Tamás Micsik; András Lőrincz; János Gál; Richard Schwab; István Peták
• Keywords: Histology; ATP Binding Cassette Transporter, Subfamily B; Research; Remission Induction; Pathology and Forensic Medicine; 3. Good health; Arthritis, Rheumatoid; 03 medical and health sciences; Methotrexate; Treatment Outcome; 0302 clinical medicine; Antirheumatic Agents; Case-Control Studies; Leukocytes; Humans; Multidrug Resistance-Associated Proteins; Biomarkers

Rheumatoid Arthritis is a chronic disease leading to decreased quality of life with rather variable response rate Disease Modifying Anti Rheumatic Drugs. Methotrexate (MTX) the gold standard therapy in Arthritis. The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called P-glycoprotein-170 transporters can alter intracellular concentration different drugs. an MRP1 substrate thus functional activity might have clinical impact on efficiency Methotrexate-therapy Arthritis.We compared Activity Factors (MAF) MDR1 Peripheral Blood Leukocytes 59 patients various MTX-therapy (MTX-responder, MTX-resistant MTX-intolerant RA-groups) 47 non-RA controls six leukocyte subpopulations (neutrophil leukocytes, monocytes, lymphocytes, CD4+, CD8+ CD19+ cells). There was MAF RA non- healthy subpopulations. significant difference between values MTX-responder MTX intolerant groups. But we not found differences -groups.Our results suggest that does seem affect Arthritis-patients, but it be useful predicting MTX-side effects. We demonstrated MDR-activity almost 60 patients, which interpreted as sign immune-suppressive effect MTX-treatment.